Loading...
Bilateral Trade Intelligence · $976 Total Trade · 4 Foreign Suppliers · 4 Indian Buyers · DGFT Verified · Updated March 2026
India imported $976 worth of pharmaceutical formulations from Tunisia across 11 verified shipments, from 4 foreign suppliers to 4 Indian buyers. The top suppliers are M/S. GAL PHARMA ($921) and LES LABORATORIES MEDIS S.A. ($39). The leading products are Rivaroxaban ($618) and Amoxicillin ($303). Average shipment value: $89.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Rivaroxaban | $618 | 63.3% |
| 2 | Amoxicillin | $303 | 31.0% |
| 3 | Semaglutide | $39 | 4.0% |
| 4 | Nilotinib | $10 | 1.0% |
| 5 | Sorafenib | $7 | 0.7% |
India imports 5+ pharmaceutical formulations from Tunisia with a combined trade value of $976. Key products include Rivaroxaban ($618), Amoxicillin ($303), Semaglutide ($39), Nilotinib ($10), Sorafenib ($7). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 11 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Tunisia, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Tunisia buyers, regulatory requirements, and logistics for that specific product corridor. Products include — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
4 Indian pharmaceutical companies export finished formulations to Tunisia. Leading exporters include M/s. Gal Pharma, Les Laboratories Medis S.a., Lino Pharma, Societe Thera S A. The top exporter accounts for 94.3% of total India–Tunisia pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Tunisia and India has experienced modest activity from 2022 to 2026. During this period, India imported a total of $976 USD worth of pharmaceutical formulations from Tunisia, distributed across 11 shipments. The average shipment value stood at $89 USD, indicating a consistent but limited trade volume. Tunisia's pharmaceutical exports to India were facilitated by four suppliers, while four Indian buyers engaged in these imports. The primary products imported included Rivaroxaban, Amoxicillin, Semaglutide, Nilotinib, and Sorafenib, with Rivaroxaban accounting for 63.3% of the total import value. This suggests a focused yet niche market presence for Tunisian pharmaceutical products in India.
Tunisia's contribution to India's pharmaceutical imports remains relatively minor. In 2024, India imported pharmaceutical products valued at $167.50 million, with Tunisia's share being a mere $94 USD. This underscores Tunisia's limited penetration in the Indian pharmaceutical market. The imports predominantly consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicating Tunisia's role as a supplier of generic medications rather than innovative or patented drugs.
4 companies in Tunisia import pharmaceutical formulations from India. Top buyers include Jeevan Scientific Technology Limited, Shaily Engineering Plastics Limited, Spinos Life Science And Research Privatelimited, Spinos Life Science And Research Private Limited. The largest buyer accounts for 94.3% of India–Tunisia pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Tunisia specifically affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) in India has maintained its existing regulatory framework for foreign pharmaceutical imports, without introducing new measures that would impact the importation of Tunisian pharmaceutical products. Similarly, Tunisia's National Drug Regulatory Authority has not implemented changes that would influence the export of pharmaceuticals to India.
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
For Tunisian pharmaceutical companies aiming to export to India, obtaining registration with the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:
1. Online Application: Applicants must visit the CDSCO SUGAM portal and create an account by providing necessary details such as applicant type, username, password, and contact information.
2. Form Submission: After account creation, the applicant selects the appropriate registration form (Form 40 for importers) and fills in organizational details, including the Corporate Identification Number (CIN), address, and contact information.
3. Document Upload: Essential documents include identity proof, address proof, manufacturing license, and an undertaking granted by a government authority for the registration of tests, drugs, or medical devices.
4. Verification and Approval: Upon submission, the application undergoes verification by CDSCO officials. If the application meets all requirements, the registration is approved, allowing the company to import pharmaceutical products into India.
The entire process can take several months, depending on the completeness of the application and the efficiency of the regulatory review.
India requires that foreign pharmaceutical manufacturers adhere to Good Manufacturing Practices (GMP) standards as outlined by the World Health Organization (WHO). Tunisian manufacturing sites must obtain WHO prequalification, which involves a rigorous assessment of manufacturing facilities, quality control systems, and compliance with international standards. Additionally, CDSCO conducts inspections of foreign manufacturing sites to ensure compliance with Indian regulations. These inspections assess the manufacturing processes, quality control measures, and overall facility conditions to ensure that imported pharmaceutical products meet the safety and efficacy standards required in India.
To import pharmaceutical products into India, Tunisian companies must secure an import license (Form 10) from CDSCO. This license authorizes the importation of specific pharmaceutical products and is valid for a specified period. Alongside the import license, a registration certificate is required, confirming that the imported products are approved for sale in India. A No Objection Certificate (NOC) from the manufacturer may also be necessary, especially if the products are patented or have exclusive distribution rights. Additionally, a test license may be required for certain products, allowing them to be tested in India before distribution. Customs procedures involve the submission of these documents to Indian customs authorities, who verify compliance with all regulatory requirements before clearing the goods for entry into the country.
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Tunisia to India are predominantly generic medications, with a significant emphasis on cardiovascular and infectious disease treatments. Rivaroxaban, an anticoagulant used to prevent blood clots, leads the imports, accounting for 63.3% of the total import value. Amoxicillin, a widely used antibiotic, follows with 31.0%, indicating a steady demand for antibiotics in the Indian market. Other imported products include Semaglutide, Nilotinib, and Sorafenib, which are used in the treatment of diabetes, cancer, and liver diseases, respectively. This trend reflects India's ongoing need for affordable generic alternatives to branded medications.
The imports from Tunisia to India primarily consist of generic formulations, with limited presence of innovative drugs or novel therapies. The focus remains on providing cost-effective alternatives to branded medications, particularly in the cardiovascular and infectious disease segments. There is a minimal presence of advanced therapies or specialty products in the current import portfolio, suggesting that Tunisian pharmaceutical companies have yet to establish a foothold in India's high-end pharmaceutical market.
India's demand for pharmaceutical imports from Tunisia is driven by several factors:
1. Patent Protection: The expiration of patents for certain branded drugs creates opportunities for generic manufacturers to supply cost-effective alternatives.
2. Technology Gaps: Tunisian manufacturers may offer formulations or dosages not readily available from domestic producers, filling specific market needs.
3. Quality Requirements: Tunisian pharmaceutical products, adhering to WHO-GMP standards, meet the quality expectations of Indian consumers and regulatory authorities.
4. Disease Burden: The prevalence of diseases such as cardiovascular conditions and infections in India drives the need for effective and affordable treatments, which Tunisian imports can fulfill.
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The MFN tariff rates are applied to imports from countries with which India does not have a Free Trade Agreement (FTA). The basic customs duty is levied on the imported goods, and the IGST is applicable to the value of the goods plus the customs duty. A health cess is also imposed on certain pharmaceutical imports to fund health initiatives. These duties and taxes collectively impact the final cost of imported pharmaceutical products in India.
As of March 2026, there is no Free Trade Agreement (FTA) between India and Tunisia that offers preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), and trade relations are governed by WTO rules and regulations. There have been no significant bilateral negotiations or agreements that have altered the standard tariff structures for pharmaceutical imports between the two nations.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the rejection of patents on new forms of known substances unless they demonstrate enhanced efficacy. This provision has implications for the importation of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Imported drugs may be subject to price controls, which can affect their market competitiveness compared to domestic alternatives.
IMPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Tunisia to India are typically transported via sea routes, with major ports such as the Port of Tunis in Tunisia and the Port of Mumbai in India serving as key transit points. The transit time for sea shipments ranges from 20 to 30 days, depending on the specific ports and shipping lines used. Air freight options are also available, offering faster delivery times but at a higher cost. The reliability of these routes is generally high, with established shipping lines and logistics providers facilitating the movement of goods.
The Port of Tunis is the primary export port for pharmaceutical products in Tunisia, equipped with facilities to handle containerized cargo efficiently. In India, the Port of Mumbai is a major import hub for pharmaceutical goods, offering advanced infrastructure and customs facilities to process international shipments. Both ports are well-connected to their respective hinterlands, ensuring smooth distribution of imported pharmaceutical products within the countries.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which involves the verification of import documentation, including the import license, registration certificate, and other required documents. The Central Drugs Standard Control Organisation (CDSCO) may conduct testing of pharmaceutical products to ensure compliance with Indian
India exported pharmaceuticals worth $976 to Tunisia across 11 verified shipments.
1. M/S. GAL PHARMA — $921. 2. LES LABORATORIES MEDIS S.A. — $39. 3. LINO PHARMA — $10. Total: 4 suppliers.
1. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED — $921. 2. SHAILY ENGINEERING PLASTICS LIMITED — $39. 3. SPINOS LIFE SCIENCE AND RESEARCH PRIVATELIMITED — $10. 4 buyers total.
1. Rivaroxaban ($618, 63.3%); 2. Amoxicillin ($303, 31.0%); 3. Semaglutide ($39, 4.0%); 4. Nilotinib ($10, 1.0%); 5. Sorafenib ($7, 0.7%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $976 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$89 per consignment across 11 shipments.
4 Indian companies. Largest: M/S. GAL PHARMA with $921.
TransData Nexus covers 4 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 11 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4 Exporters
4 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists